A newly developed LC/MSMS method is suitable for determining edoxaban concentrations in human plasma and was successfully applied to evaluate pharmacokinetics in post-surgical patients.
Answers are grounded in this paper and cite their sources.
Validated LC/MSMS assay supports edoxaban plasma quantification; extends PK data to post-surgical patients but remains hypothesis-generating.
Edoxaban was extracted from human plasma by simple protein precipitation with acetonitrile, followed by quantitative determination using a liquid chromatography-mass spectrometry method. The recoveries of edoxaban and the internal standard (ticlopidine) from human plasma were >85%, and the within- and between-day coefficients of variation were within 15%. The limit of quantification in human plasma was 1 ng/mL. The concentration of edoxaban in blood decreased at room temperature, but remained unchanged for 1 week at 4°C. On the other hand, the concentration in plasma at both -20 and -80°C remained unchanged for 5 months. These results indicated that blood samples should be centrifuged immediately or stored at 4°C, and that plasma samples should be stored below -20°C until analysis. This method was applied to human plasma obtained from four patients after total knee arthroplasty. Analysis of edoxaban pharmacokinetics demonstrated an absorption time lag of 4h, a maximum concentration of 110 ± 26 ng/mL and an oral clearance of 37 ± 16 L/h. The analytical methods established in this study will be suitable for determining the concentrations of edoxaban in human plasma.
No takes yet. Share an insight, caveat, or question.
Hanada et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: